The $251 Million Bet on Making Drugs Where There's No Gravity

From SpaceX Engineer to Space Pharmacist

Varda was founded in January 2021 by Will Bruey, a former SpaceX engineer, and Delian Asparouhov, a Founders Fund partner. Bruey serves as CEO; Asparouhov is president. Their insight was simple but bold: decades of ISS experiments had shown that microgravity improves crystallization, yet nobody had built a commercial business around it.

The company's approach skips the space station entirely. Instead, Varda launches its own spacecraft with a built-in manufacturing module, processes materials in orbit, then brings everything home in a reentry capsule. Think of it as a self-contained factory that happens to be hurtling around the planet at 17,000 miles per hour.

The first mission, called Winnebago-1 (yes, really), launched on a SpaceX rocket in June 2023. It crystallized ritonavir, an HIV drug, in orbit and returned to Earth in February 2024. That landing made Varda the first commercial spacecraft company to touch down on U.S. soil, at Utah's Test and Training Range.

Since then, the pace has been relentless. Varda flew four more missions in 2025, and a sixth completed reentry in May 2026. All but one mission successfully returned their capsules. By mission four, Varda was using its own satellite bus and its own heat shield, steadily bringing more of the technology in-house.

The Business Model: Contract Manufacturing, but Make It Orbital

Varda isn't trying to become a pharma company. It's positioning itself as a contract manufacturer for drugmakers and government clients who want access to microgravity processing. Think of it like a CDMO (contract development and manufacturing organization), except your factory orbits 250 miles above the Earth.

The company recently added former Pfizer biotech executive Mikael Dolsten to its board, a signal that it's serious about pharma credibility. About 18% of Varda's employees now have pharmaceutical backgrounds, according to Asparouhov. The company has said it expects to serve publicly traded biopharma companies and government clients, though it hasn't named specific customers publicly.

The near-term focus is on small-batch, high-value products rather than mass-market generics. That makes sense: you're not going to launch ibuprofen into space when you can make it perfectly fine in New Jersey. But for specialty biologics and complex molecules where crystal quality drives clinical outcomes, the math could work.

A Crowded Frontier (Sort Of)

Varda isn't completely alone in this niche, but its lead is significant. SpacePharma offers microgravity research services for drug development. ATMOS Space Cargo and In Orbit Aerospace appear in competitor databases. Redwire operates manufacturing hardware on the International Space Station, including 3D printing and fiber optics production.

But none of these competitors match Varda's combination of dedicated spacecraft, reentry capability, and pharmaceutical focus. Most are either doing research-stage work on the ISS or building broader space manufacturing platforms without the pharma specialization. Varda has flown six missions and landed five capsules. That operational track record is hard to replicate.

The Bull Case and the Bear Case

The optimistic view is straightforward: Varda has proven the technology works, built a reusable platform, attracted blue-chip investors, and is ramping its mission cadence. If even a handful of specialty drugs benefit significantly from microgravity crystallization, this could be a multi-billion-dollar market.

The skeptical view deserves airtime too. A $1.6 billion valuation for a company that hasn't yet produced its first commercially approved medicine made in space requires a lot of faith in future execution. The science is promising but case-specific; not every molecule will cooperate. And the economics of launching payloads into orbit, processing them, and returning them safely still need to pencil out at commercial scale.

The truth probably lives somewhere in the middle. Space pharma isn't going to replace traditional manufacturing anytime soon. But it doesn't need to. If Varda can carve out a defensible position in high-value, crystal-quality-sensitive products, it could build something genuinely new.

The Bigger Picture

Five years ago, "space-based pharmaceutical manufacturing" was the kind of phrase that got you politely escorted out of investor meetings. Now it has $598 million in funding, a unicorn valuation, and six successful orbital missions behind it.

Varda's Series D doesn't prove that space pharmacies are inevitable. But it proves that serious money believes they're plausible. And in biotech, that's often how the impossible becomes inevitable: one expensive, slightly crazy bet at a time.

The Pill That Could Replace the Needle in Breast Cancer Treatment

Genentech's oral pill giredestrant just posted Phase 3 results in the NEJM that could shake up breast cancer treatment. In patients whose cancers outsmarted standard therapy, it cut the risk of progression by up to 62%, and Roche already has an FDA application under review.